DPP4 and Hypoglycemia: Among the various classes of oral antidiabetic medications, dipeptidyl peptidase-4 (DPP-4) inhibitors have gained recognition for their ability to enhance insulin secretion and suppress glucagon release in a manner dependent on glucose levels, which helps reduce the risk of hypoglycemia [2].